Streptococcus pneumoniae Resistance and Treatment Guidelines

Introduction to Resistance Patterns

The American Academy of Otolaryngology-Head and Neck Surgery recommends using high-dose amoxicillin (4 g/day in adults, 90 mg/kg/day in children) or high-dose amoxicillin-clavulanate (2 g orally twice daily) as first-line empiric therapy for suspected Streptococcus pneumoniae infections in the United States, reserving respiratory fluoroquinolones for penicillin-allergic patients or treatment failures 1, 2

Penicillin nonsusceptibility affects nearly 40% of S. pneumoniae strains causing disease in adults in the United States, with 12% of isolates being penicillin-intermediate and 25% being penicillin-resistant based on recent surveillance data 3

Macrolide resistance averages 28-29% nationally, but varies geographically, with 71% of macrolide resistance being efflux-mediated and 27% involving target site modification 1, 4
The high prevalence of macrolide-resistant S. pneumoniae (>40%) makes macrolides inappropriate for first-line empiric therapy 1

For low-risk patients, the American Academy of Otolaryngology-Head and Neck Surgery recommends using high-dose amoxicillin (1 g orally three times daily) as first-line therapy 1, 5
For high-risk patients, the American Academy of Otolaryngology-Head and Neck Surgery recommends using high-dose amoxicillin-clavulanate (2 g orally twice daily or 90 mg/kg/day twice daily) 1
Risk factors requiring escalation include geographic regions with >10% invasive penicillin-nonsusceptible S. pneumoniae, age >65 years, recent antibiotic use, recent hospitalization, severe infection, immunocompromised status, and chronic comorbidities 1, 6

For non-type I hypersensitivity, the American Academy of Otolaryngology-Head and Neck Surgery recommends using combination therapy with clindamycin plus a third-generation oral cephalosporin (cefixime or cefpodoxime) 1
For type I hypersensitivity, the American Academy of Otolaryngology-Head and Neck Surgery recommends using respiratory fluoroquinolones (levofloxacin 750 mg daily or moxifloxacin 400 mg daily) 1

The American Academy of Otolaryngology-Head and Neck Surgery recommends using parenteral ceftriaxone or cefotaxime, which maintain >99% coverage even against intermediately resistant strains 2

The American Academy of Otolaryngology-Head and Neck Surgery advises against using macrolides, trimethoprim-sulfamethoxazole, cefdinir, and ciprofloxacin for empiric therapy due to high resistance rates 1, 2, 7, 8

The standard duration of therapy is 5-10 days for community-acquired pneumonia, with similar success rates 1
Shorter courses (5 days) reduce adverse events without compromising efficacy 1

The pneumococcal conjugate vaccine has contributed to decreased resistance prevalence since 2000 3
Fluoroquinolone resistance remains a class effect, with resistance to one fluoroquinolone predicting resistance to others 7, 8

In Europe, rates of Streptococcus pneumoniae resistance vary substantially by country, with higher resistance in France and Israel historically, though both showed decreasing trends, according to the European Society of Clinical Microbiology and Infectious Diseases 9
Belgium, Lithuania, and Norway demonstrated significant decreases in penicillin-nonsusceptible S. pneumoniae (PNSP), as reported by the European Centre for Disease Prevention and Control 9
The Netherlands and Germany maintain lower resistance rates due to strict antibiotic usage limitations, as recommended by the European Society of Clinical Microbiology and Infectious Diseases 10
In the Eastern and Southern Mediterranean, overall 26% of invasive isolates were non-susceptible to penicillin, with Algeria reporting 44% and Lebanon 40% penicillin nonsusceptibility, according to the World Health Organization 9

Intermediate resistance (MIC 0.1-1.0 mg/mL) is not clinically important for pneumonia treatment when standard doses are used, though it matters for meningitis, as stated by the Infectious Diseases Society of America 10, 11
High-grade resistance (MIC ≥4 mg/mL) may be clinically significant even for pneumonia, according to the American Thoracic Society 10
Macrolide resistance is primarily efflux-mediated (71%, modest resistance, MIC 1-32 mg/L) or involves target site modification (27%, high-level resistance, MIC ≥64 mg/L), as reported by the European Respiratory Society 12

For pneumonia, intermediate penicillin resistance does not predict treatment failure with appropriate beta-lactam dosing, as recommended by the American College of Chest Physicians 10, 11
For meningitis, all resistance levels are clinically significant due to lower CSF antibiotic concentrations, and ceftriaxone or cefotaxime with vancomycin is recommended until susceptibility is known, according to the Infectious Diseases Society of America 10, 11

Serotype 19A with high-level penicillin resistance increased from 6.7% to 35% between 1998 and 2005 in the United States, as reported by the Centers for Disease Control and Prevention 9
Multidrug-resistant serotype 19A strains are increasing in Spain and France, according to the European Centre for Disease Prevention and Control 9